104 results about "Phenylacetones" patented technology

The present invention provides, among other things, methods of treating phenylketonuria (PKU), including administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH) at an effective dose and an administration interval such that at least one symptom or feature of PKU is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.

The invention discloses a novel method for preparing bupropion hydrochloride. According to the invention, m-chlorophenylacetone is taken as an initiator, then is brominated in a hydrobromic acid-hydrogen peroxide system, 3'-chlorine-alpha-bromophenyl ethyl ketone is synthesized; then through replacement by tert-butylamine and acidification by HCl-absolute ethyl alcohol, bupropion hydrochloride is obtained. The preparation method of bupropion hydrochloride replaces traditional bromine bromination, pollution can be effectively reduced, damage due to bromine volatilization on the operators can be greatly mitigated, and the method has the advantages of simple operation, low cost, high yield, and less side reaction, and is very suitable for industrial production.

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and / or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, [e.g., treating hyperphenylalaninemia, (including phenylketonuria)], and other disorders (including cancer).

The invention relates to metabolism of enteric microorganisms and phenylalanine and phenylpyruvic acid of the enteric microorganisms, and provides a composition containing phenyllactic acid or salts of phenyllactic acid and phenylpyruvic acid or salts of phenylpyruvic acid and used for preventing or / and treating insulin resistance and related diseases, use of the composition in preparation of a medicine or food for improving, preventing or treating insulin resistance and related diseases, and a method for preventing or treating insulin resistance and related diseases. The related diseases include intestinal dysbacteriosis, metabolic syndrome, obesity, diabetes, podagra and tumors.

The invention discloses a method for preparing dapoxetine intermediate by using carbonyl reductase. In the method, a crushed mixed solution of wet cells obtained by induction culture of engineered bacteria containing the carbonyl reductase gene after ultrasonication is used as a catalyst, and 3-chlorophenylacetone is used as a substrate, and NADH and isopropanol are added, and a phosphate buffer with a pH of 6.5. -7.5 is used as a reaction medium to constitute a reaction system. The reaction system is complete with magnetic stirring at 30-40 DEG C. The reaction solution is separated and purified to obtain (R)-3-chlorophenylpropanol. The invention adopts a new type of carbonyl reductase to catalyze a reduction reaction, has the advantages of small amount of biocatalyst, mild reaction conditions (30-40 DEG C), short reaction time (6-12 hours), 95.2% of yield coefficient, and good optical purity (greater than 99), and the like.

Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria.

Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.

The invention discloses a method of preparing chiral phenylalanine by catalysis and asymmetric reduction of a marine strain, and relates to chiral phenylalanine. Bacillus nanhaiensis DSP-15A2 is preserved in CGMCC (China General Microbiological Culture Collection Center) with a preservation number of CGMCC No. 8969. The method comprises the steps of adding the bacillus nanhaiensis to a 2216L culture medium for culture to obtain a fermentation solution, centrifuging to obtain a cell, resuspending and washing with a buffer solution, preparing a cell solution, adding phenylpyruvic acid and an amino donor to the cell solution as substrates, adding an auxiliary substrate for cyclic regeneration of coenzyme, performing a reaction to obtain a reaction solution containing a product namely L-phenylalanine, centrifuging to remove deposit, adding equivalent methanol to a supernate, shaking and mixing uniformly, centrifuging to remove deposit (protein), diluting the supernate, then measuring, detecting the concentration of phenylpyruvic acid by high performance liquid chromatography, and measuring the concentration of the product namely L-phenylalanine and an excessive value of an antipode by the high performance liquid chromatography.

The invention relates to a fecal biomarker for diagnosing or preventing diabetes mellitus, a detection reagent and application of the fecal biomarker. The excrement biomarker for diagnosing or preventing diabetes mellitus provided by the invention comprises one or more of 2-hydroxyhexanoic acid, phenylalanine, valine, acetyltryptophan, nonadecanoic acid, oxalic acid, picolinic acid, alpha-hydroxyisobutyric acid, indoleacetic acid, p-hydroxyphenylacetic acid, acetic acid, thyroxine, 4-hydroxyphenylpyruvic acid, myristic acid or phenylacetic acid. The fecal biomarker provided by the invention is high in sensitivity and specificity and good in predictability, and can be used for early diagnosis or prevention of diabetic people, especially diabetic people exposed by combination of long-term low-dose radiation and high-glucose and high-fat diet.

The invention discloses a water-solubility polyphenylene sulfide which has a structure formula as shown in the specification. The polyphenylene sulfide dissolves in water and saturated salt water and does not dissolve in methyl pyrrolidone, dimethylacetylamide, tetrahydrofuran, toluene, acetone, chloroform and ethanol; or the polyphenylene sulfide dissolves in the water and the saturated salt water, slightly dissolves in methyl pyrrolidone, dimethylacetylamide and ethanol, and does not dissolve in tetrahydrofuran, toluene, acetone and chloroform, wherein R is N<+>(CH3)3CL<->, NH<+>(CH3)2CL<->, N<+>(CH2CH2OH)3CL<-> and NH<+>(CH2CH2OH)2CL<->. Or the invention further discloses a preparation method of the water-solubility polyphenylene sulfide. The water-solubility polyphenylene sulfide prepared by the invention has the advantages of good water-solubility, temperature resistance and salt resistance, can be expected to not only broaden application of the water-solubility polyphenylene sulfide in the field of water-solubility functional polymer but also is applied to the fields with worst working environment, such as oil field, paper making, waste water treatment and the like.